A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; Peristeen Plus, a transanal irrigation system; and Peristeen Light, a low-volume transanal irrigation. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as erectile dysfunction, urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Financial Summary
| Share Statistics | CLPBY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $15,037.1 | $334.8 | 83% |
|
| Shares Out (Mil) | 34.7 | 41.7 | 40% |
|
| Institutional Ownership | 39.8% | 77.3% | 17% |
|
| Float (Mil) | 144.6 | 34.7 | 69% |
|
| Beta | 0.50 | 0.86 | 28% |
|
| Avg Daily Volume (000s) | 323 | 266 | 52% |
|
| Price Change (52-week) |
(30.6%) | 60.7% | 25% |
|
| Growth | CLPBY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 8.4% | 11.8% | 52% |
|
| Net Income (5yr) | (2.9%) | (5.8%) | 36% |
|
| EPS (5yr) | (4.0%) | 10.7% | 26 |
|
| Dividends (5yr) | 4.9% | 0.0% | 95% |
|
| Cash Flow (5yr) | na | (16.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 2 | 2 | |
| Current EPS | $0.094 | $0.304 | $0.416 | |
| Month Ago EPS | $0.944 | $3.757 | $4.049 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $0.965 | $3.819 | $4.107 | |
| Year/Year Chg | na | (88.0%) | na | |
| Financials | CLPBY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $4,327 | $152 | 73% |
|
| Net Income (TTM) (Mil) | $325 | ($11) | 74% |
|
| EPS (TTM) | $1.442 | ($0.500) | 66% |
|
| Operating Cash Flow (TTM) (Mil) | $1,172 | ($2) | 83% |
|
| Net Cash Flow (TTM) (Mil) | $53 | $1 | 71% |
|
| Long-Term Debt (Q1) (Mil) | $3,393 | $22 | 81% |
|
| Enterprise Value (Q1) (Mil) | $17,638 | $304 | 82% |
|
| Valuation | CLPBY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.88 | na |
|
| P/E | na | 30.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.9 | na |
|
| Ratios | CLPBY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 67.5% | 59.1% | 79% |
|
| Net Margin | 7.5% | (7.7%) | 57% |
|
| ROA | 4.5% | (13.7%) | 70% |
|
| ROE | 14.6% | (15.9%) | 70% |
|
| Liabilities to Assets | 72.5% | 44.9% | 68% |
|
| F-Score | na | 4 | na |
|
Coloplast A/S did not pass any screens on 7/30/2026.